|
業務類別
|
Biotechnology |
|
業務概覽
|
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules thatare designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
| 公司地址
| One Broadway, 14th Floor, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 857 357-7000 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.nuvalent.com |
| 員工數量
| 228 |
| Mr. Henry E. Pelish |
Chief Scientific Officer |
-- |
26/02/2026 |
| Dr. Christopher D. Turner, M.D. |
Chief Medical Officer |
美元 520.10K |
26/02/2026 |
| Ms. Alexandra Balcom, C.P.A.,M.B.A. |
Chief Financial Officer, Principal Accounting Officer and Treasurer |
美元 475.50K |
26/02/2026 |
| Dr. Deborah Miller, J.D.,PhD |
Chief Legal Officer and Secretary |
美元 467.00K |
26/02/2026 |
| Ms. Darlene Noci, A.C.I.S. |
Chief Development Officer |
美元 467.40K |
26/02/2026 |
| Dr. James R. Porter, PhD |
Director, Chief Executive Officer and President |
美元 652.10K |
28/04/2026 |
|
|
| Ms. Christy J. Oliger |
Independent Director |
28/04/2026 |
| Mr. Grant C. Bogle |
Independent Director |
28/04/2026 |
| Ms. Anna Protopapas, M.B.A. |
Chairman of the board |
28/04/2026 |
| Dr. Joseph Pearlberg, M.D.,PhD |
Independent Director |
28/04/2026 |
| Dr. James R. Porter, PhD |
Director, Chief Executive Officer and President |
28/04/2026 |
| Dr. Cameron A. Wheeler, PhD |
Independent Director |
28/04/2026 |
| Dr. Michael L. Meyers, M.D.,PhD |
Independent Director |
28/04/2026 |
| Dr. Sapna Srivastava, PhD |
Independent Director |
28/04/2026 |
| Mr. Ron Squarer |
Independent Director |
28/04/2026 |
|
|
|
|
